A retrospective study to determine difference in HRU between 7 + 3 and CPX-351 in acute myeloid leukemia patients treated with HMA-Venetoclax
Latest Information Update: 10 Jan 2023
At a glance
- Drugs Cytarabine/daunorubicin (Primary) ; Venetoclax
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
Most Recent Events
- 10 Jan 2023 New trial record
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition